AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Condition:   Head and Neck Cancer Interventions:   Drug: AMD3100;   Drug: Pembrolizumab Sponsors:   Massachusetts General Hospital;   Merck Sharp & Dohme Corp.;   AperiSys, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials